Clinical Trials
2 trialsNCT02662296 2017-09-27
Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 2 Withdrawn
NCT01659047 2012-09-07
A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 2 Withdrawn